Objective:

To evaluate adherence to risk management programs (RMPs) during targeted therapy use and examine its association with infection-related outcomes in patients with autoimmune diseases.

Approach:

Key Findings:

• Adherence to RMPs varied among patients, particularly after treatment initiation.
• Inconsistent RMP implementation may lead to differential infectious outcomes.
• Specific safety concerns associated with targeted therapies include serious infections and cardiovascular events.

Interpretation:

Real-world adherence to RMPs is crucial for managing risks associated with targeted therapies in autoimmune diseases.

Limitations:

• The study was retrospective and conducted at a single center, which may limit generalizability.
• Potential biases in data collection and patient selection.

Conclusion:

Adherence to RMPs is essential for optimizing safety in patients undergoing targeted therapy for autoimmune diseases.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.